RegeneRx Biopharmaceuticals, Inc. (RGRX)'s Tß4 Promotes Recovery of Peripheral Neuropathy in Type II Diabetic Mice  
8/30/2012 10:11:22 AM

ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) reports that U.S. researchers have found that Thymosin Beta 4 (Tß4) promotes statistically significant recovery of peripheral neuropathy in type II diabetic mice including recovery of neurovascular dysfunction in the sciatic nerve and recovery of neurological function. Peripheral neuropathy is one of the most common complications of diabetes mellitus and affects 60%-70% of patients with diabetes.